1	The	the	DT	_	2	det	_
2	board	board	NN	_	7	nsubj	7:A0=PAG
3	of	of	IN	_	2	prep	_
4	AstraZeneca	astrazeneca	NNP	_	5	nn	_
5	PLC	plc	NNP	_	3	pobj	_
6	has	have	VBZ	_	7	aux	_
7	rejected	reject	VBN	pb=reject.01	0	root	_
8	the	the	DT	_	14	det	_
9	increased	increase	VBN	p2=JJ|pb=increase.01	14	amod	_
10	US$	us$	$	p2=NNP	12	quantmod	_
11	119	0	CD	_	12	number	_
12	billion	#crd#	CD	_	14	nn	_
13	takeover	takeover	NN	p2=WDT	14	nn	_
14	offer	offer	NN	_	7	dobj	7:A1=PPT;9:A1=PPT
15	from	from	IN	_	14	prep	_
16	US	us	NNP	_	20	nn	_
17	pharmaceuticals	pharmaceutical	NNS	_	20	nn	_
18	firm	firm	JJ	p2=NN	20	nn	_
19	Pfizer	pfizer	NNP	_	20	nn	_
20	Inc	inc	NNP	_	15	pobj	_
21	,	,	,	_	20	punct	_
22	a	a	DT	_	23	det	_
23	decision	decision	NN	_	20	appos	26:A0=PAG
24	that	that	WDT	_	26	nsubj	26:R-A0
25	has	have	VBZ	_	26	aux	_
26	led	lead	VBN	pb=lead.03	23	rcmod	_
27	to	to	IN	_	26	prep	26:A2=PRD
28	a	a	DT	_	30	det	_
29	sharp	sharp	JJ	_	30	amod	_
30	slide	slide	NN	_	27	pobj	_
31	in	in	IN	_	30	prep	_
32	the	the	DT	_	34	det	_
33	UK	uk	NNP	_	34	nn	_
34	company	company	NN	_	37	poss	_
35	's	's	POS	_	34	possessive	_
36	share	share	NN	_	37	nn	_
37	price	price	NN	_	31	pobj	_
38	as	as	IN	_	40	mark	_
39	investors	investor	NNS	_	40	nsubj	40:A0
40	think	think	VBP	pb=think.01	26	advcl	_
41	it	it	PRP	_	43	nsubj	43:A0=PAG
42	effectively	effectively	RB	_	43	advmod	43:AM-MNR
43	brings	bring	VBZ	pb=bring.01	40	ccomp	40:A1=PPT
44	an	an	DT	_	45	det	_
45	end	end	NN	_	43	dobj	43:A1=PPT
46	to	to	IN	_	45	prep	_
47	the	the	DT	_	53	det	_
48	protracted	protract	VBN	p2=JJ|pb=protract.01	53	amod	_
49	and	and	CC	_	48	cc	_
50	increasingly	increasingly	RB	_	51	advmod	_
51	bitter	bitter	JJ	_	48	conj	_
52	takeover	takeover	NN	_	53	nn	_
53	saga	saga	NN	_	46	pobj	48:A1=PPT
54	.	.	.	_	7	punct	_

1	Pfizer	pfizer	NNP	p2=NN	14	nsubj	14:A0=PAG;21:A0
2	,	,	,	_	1	punct	_
3	the	the	DT	_	4	det	_
4	world	world	NN	_	8	poss	_
5	's	's	POS	_	4	possessive	_
6	No.	no.	NN	_	8	nn	_
7	2	0	CD	_	6	num	_
8	drugmaker	drugmaker	NN	p2=JJR	1	appos	_
9	by	by	IN	_	8	prep	_
10	revenue	revenue	NN	_	9	pobj	_
11	,	,	,	_	1	punct	_
12	has	have	VBZ	_	14	aux	_
13	been	be	VBN	_	14	aux	_
14	pursuing	pursue	VBG	pb=pursue.01	0	root	_
15	No.	no.	NN	_	17	nn	_
16	8	0	CD	_	15	num	_
17	AstraZeneca	astrazeneca	NNP	_	14	dobj	14:A1=PPT
18	since	since	IN	_	14	prep	14:AM-TMP
19	January	january	NNP	_	18	pobj	_
20	,	,	,	_	14	punct	_
21	saying	say	VBG	pb=say.01	14	advcl	14:AM-ADV
22	that	that	IN	_	25	complm	_
23	their	their	PRP$	_	24	poss	_
24	businesses	business	NNS	_	25	nsubj	25:A1=PPT;29:A1=PPT
25	are	be	VBP	pb=be.01	21	ccomp	21:A1=PPT
26	complementary	complementary	JJ	_	25	acomp	25:A2=PRD
27	and	and	CC	_	25	cc	_
28	would	would	MD	_	29	aux	29:AM-MOD
29	be	be	VB	pb=be.01	25	conj	_
30	stronger	strong	JJR	p2=RBR	29	acomp	29:A2=PRD
31	together	together	RB	_	29	advmod	29:AM-MNR
32	.	.	.	_	14	punct	_

1	On	on	IN	_	5	prep	5:AM-TMP
2	Sunday	sunday	NNP	_	1	pobj	_
3	,	,	,	_	5	punct	_
4	it	it	PRP	_	5	nsubj	5:A0
5	said	say	VBD	pb=say.01	0	root	_
6	it	it	PRP	_	7	nsubj	10:A0=PAG;7:A1=PPT
7	was	be	VBD	pb=be.01	5	ccomp	5:A1=PPT
8	ready	ready	JJ	_	7	acomp	7:A2=PRD
9	to	to	TO	_	10	aux	_
10	raise	raise	VB	pb=raise.01	8	xcomp	_
11	its	its	PRP$	_	17	poss	_
12	stock	stock	NN	_	17	nn	_
13	-	-	HYPH	_	12	hyph	_
14	and	and	CC	_	12	cc	_
15	-	-	HYPH	_	16	hyph	_
16	cash	cash	NN	_	12	conj	_
17	offer	offer	NN	_	10	dobj	10:A1=PPT
18	by	by	IN	_	10	prep	10:AM-MNR
19	15	0	CD	_	20	num	_
20	percent	percent	NN	_	18	pobj	_
21	to	to	IN	_	10	prep	10:A4=GOL
22	US$	us$	$	_	24	quantmod	_
23	118.8	0	CD	_	24	number	_
24	billion	#crd#	CD	_	21	pobj	_
25	,	,	,	_	24	punct	_
26	or	or	CC	_	24	cc	_
27	￡70.73	￡0	CD	p2=DT	28	number	_
28	billion	#crd#	CD	_	24	conj	_
29	.	.	.	_	5	punct	_

1	Because	because	IN	_	3	mark	_
2	Pfizer	pfizer	NNP	_	3	nsubj	3:A0
3	said	say	VBD	pb=say.01	30	advcl	_
4	it	it	PRP	_	7	nsubj	7:A0=PAG;12:A0=PAG
5	would	would	MD	_	7	aux	7:AM-MOD;12:AM-MOD
6	not	not	RB	_	7	neg	7:AM-NEG;12:AM-NEG
7	raise	raise	VB	pb=raise.01	3	ccomp	3:A1=PPT
8	its	its	PRP$	_	9	poss	_
9	offer	offer	NN	_	7	dobj	7:A1=PPT
10	again	again	RB	_	7	advmod	7:AM-TMP
11	or	or	CC	_	7	cc	_
12	launch	launch	VB	pb=launch.01	7	conj	_
13	a	a	DT	_	16	det	_
14	hostile	hostile	JJ	_	16	amod	_
15	takeover	takeover	NN	_	16	nn	_
16	bid	bid	NN	p2=VBN	12	dobj	12:A1=PPT
17	over	over	IN	_	16	prep	_
18	the	the	DT	_	19	det	_
19	heads	head	NNS	_	17	pobj	_
20	of	of	IN	_	19	prep	_
21	AstraZeneca	astrazeneca	NNP	_	23	poss	_
22	's	's	POS	_	21	possessive	_
23	board	board	NN	_	20	pobj	_
24	,	,	,	_	30	punct	_
25	the	the	DT	_	26	det	_
26	prospect	prospect	NN	_	30	nsubj	30:A0=PAG;32:A1=PPT
27	of	of	IN	_	26	prep	_
28	a	a	DT	_	29	det	_
29	deal	deal	NN	_	27	pobj	_
30	looks	look	VBZ	pb=look.04	0	root	_
31	to	to	TO	_	32	aux	_
32	be	be	VB	pb=be.01	30	xcomp	30:A1=PPT
33	remote	remote	JJ	_	32	acomp	32:A2=PRD
34	,	,	,	_	30	punct	_
35	unless	unless	IN	p2=JJ	38	mark	_
36	AstraZeneca	astrazeneca	NNP	p2=JJ	37	nn	_
37	shareholders	shareholder	NNS	_	38	nsubj	38:A0=PAG
38	urge	urge	VBP	pb=urge.01	30	advcl	30:AM-ADV
39	a	a	DT	_	40	det	_
40	change	change	NN	_	38	dobj	38:A1=PPT
41	of	of	IN	_	40	prep	_
42	mind	mind	NN	_	41	pobj	_
43	.	.	.	_	30	punct	_

1	Pfizer	pfizer	NNP	_	3	nsubj	3:A0
2	has	have	VBZ	_	3	aux	_
3	said	say	VBN	p2=VBD|pb=say.01	0	root	_
4	it	it	PRP	_	5	nsubj	5:A0
5	hopes	hope	VBZ	pb=hope.01	3	ccomp	3:A1=PPT
6	AstraZeneca	astrazeneca	NNP	_	8	poss	_
7	's	's	POS	_	6	possessive	_
8	shareholders	shareholder	NNS	_	10	nsubj	10:A0=PAG
9	will	will	MD	_	10	aux	10:AM-MOD
10	push	push	VB	pb=push.02	5	ccomp	5:A1=PPT
11	for	for	IN	_	10	prep	10:A2=PRD
12	a	a	DT	_	13	det	_
13	deal	deal	NN	_	11	pobj	_
14	.	.	.	_	3	punct	_

1	Now	now	RB	_	6	advmod	6:AM-TMP
2	,	,	,	_	6	punct	_
3	AstraZeneca	astrazeneca	NNP	_	4	nn	_
4	shareholders	shareholder	NNS	p2=VBZ	6	nsubj	6:A0
5	certainly	certainly	RB	_	6	advmod	6:AM-ADV
6	think	think	VBP	pb=think.01	0	root	_
7	a	a	DT	_	8	det	_
8	deal	deal	NN	_	9	nsubj	9:A1=PPT
9	is	be	VBZ	pb=be.01	6	ccomp	6:A1=PPT
10	over	over	RB	p2=RP	9	advmod	9:A2=PRD
11	and	and	CC	_	9	cc	_
12	the	the	DT	_	13	det	_
13	company	company	NN	_	16	poss	_
14	's	's	POS	_	13	possessive	_
15	share	share	NN	_	16	nn	_
16	price	price	NN	_	17	nsubj	17:A1
17	slumped	slump	VBD	pb=slump.01	9	conj	_
18	12.9	0	CD	_	19	num	_
19	percent	percent	NN	_	17	npadvmod	17:A2=EXT
20	to	to	IN	p2=TO	17	prep	17:A4=GOL
21	￡41.90	￡0	NN	p2=CD	20	pobj	_
22	.	.	.	_	17	punct	_

1	For	for	IN	_	6	prep	6:AM-TMP
2	weeks	week	NNS	_	1	pobj	_
3	,	,	,	_	6	punct	_
4	Pfizer	pfizer	NNP	_	6	nsubj	6:A0=PAG
5	has	have	VBZ	_	6	aux	_
6	sought	seek	VBN	pb=seek.01	0	root	_
7	the	the	DT	_	8	det	_
8	board	board	NN	_	10	poss	_
9	's	's	POS	_	8	possessive	_
10	approval	approval	NN	_	6	dobj	6:A1=PPT
11	for	for	IN	_	10	prep	_
12	what	what	WP	_	15	nsubj	15:R-A1
13	would	would	MD	_	15	aux	15:AM-MOD
14	have	have	VB	_	15	aux	_
15	been	be	VBN	pb=be.01	11	pcomp	_
16	the	the	DT	_	18	det	_
17	richest	rich	JJS	_	18	amod	_
18	acquisition	acquisition	NN	_	15	attr	15:A2=PRD
19	ever	ever	RB	_	18	advmod	_
20	among	among	IN	_	18	prep	_
21	drugmakers	drugmaker	NNS	_	20	pobj	_
22	and	and	CC	_	18	cc	_
23	the	the	DT	_	27	det	_
24	third	#ord#	RB	_	26	hmod	_
25	-	-	HYPH	_	26	hyph	_
26	biggest	big	JJS	_	27	amod	_
27	deal	deal	NN	_	18	conj	_
28	in	in	IN	_	27	prep	_
29	any	any	DT	_	30	det	_
30	industry	industry	NN	_	28	pobj	_
31	,	,	,	_	6	punct	_
32	according	accord	VBG	_	6	prep	_
33	to	to	IN	_	32	prep	_
34	figures	figure	NNS	_	33	pobj	_
35	from	from	IN	_	34	prep	_
36	research	research	NN	_	37	nn	_
37	firm	firm	NN	p2=JJ	38	nn	_
38	Dealogic	dealogic	NNP	_	35	pobj	_
39	.	.	.	_	6	punct	_

1	It	it	PRP	_	3	nsubj	3:A1=PPT
2	would	would	MD	_	3	aux	3:AM-MOD
3	be	be	VB	pb=be.01	0	root	_
4	Pfizer	pfizer	NNP	_	7	poss	_
5	's	's	POS	_	4	possessive	_
6	fourth	#ord#	JJ	_	7	amod	_
7	deal	deal	NN	_	3	attr	3:A2=PRD
8	worth	worth	JJ	p2=NN	7	amod	_
9	US$	us$	$	p2=NNP	11	quantmod	_
10	60	0	CD	_	11	number	_
11	billion	#crd#	CD	_	8	npadvmod	_
12	or	or	CC	_	11	cc	_
13	more	more	JJR	_	11	conj	_
14	since	since	IN	_	11	prep	_
15	2000	0	CD	_	14	pobj	_
16	.	.	.	_	3	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	poss	_
2	's	's	POS	_	1	possessive	_
3	offer	offer	NN	_	4	nsubj	4:A1=PPT
4	comes	come	VBZ	pb=come.01	0	root	_
5	amid	amid	IN	_	4	prep	4:AM-TMP
6	a	a	DT	_	7	det	_
7	surge	surge	NN	_	5	pobj	_
8	of	of	IN	_	7	prep	_
9	other	other	JJ	_	10	amod	_
10	deals	deal	NNS	_	8	pobj	_
11	as	as	IN	p2=RB	13	mark	_
12	drugmakers	drugmaker	NNS	_	13	nsubj	13:A0=PPT
13	look	look	VBP	pb=look.01	4	advcl	4:AM-TMP
14	to	to	IN	p2=TO	13	prep	13:A1=GOL
15	either	either	CC	p2=DT	16	preconj	_
16	grow	grow	VB	p2=VBP	14	pobj	_
17	or	or	CC	_	16	cc	_
18	eliminate	eliminate	VB	pb=eliminate.01	16	conj	_
19	peripheral	peripheral	JJ	_	20	amod	_
20	assets	asset	NNS	_	18	dobj	18:A1=PPT
21	to	to	TO	_	22	aux	_
22	focus	focus	VB	pb=focus.01	18	advcl	_
23	on	on	IN	_	22	prep	22:A2=PPT
24	their	their	PRP$	_	25	poss	_
25	strengths	strength	NNS	_	23	pobj	_
26	.	.	.	_	4	punct	_

1	Those	those	DT	_	2	det	_
2	deals	deal	NNS	_	3	nsubj	3:A2=GOL
3	include	include	VBP	pb=include.01	0	root	_
4	Switzerland	switzerland	NNP	_	7	poss	_
5	's	's	POS	_	4	possessive	_
6	Novartis	novartis	NNP	_	7	nn	_
7	AG	ag	NNP	_	3	dobj	8:A0=PAG;10:A0=PAG;3:A1=PPT
8	agreeing	agree	VBG	pb=agree.01	7	partmod	_
9	to	to	TO	_	10	aux	_
10	buy	buy	VB	pb=buy.01	8	xcomp	8:A1=PPT
11	GlaxoSmithKline	glaxosmithkline	NNP	_	12	nn	_
12	PLC	plc	NNP	_	15	poss	_
13	's	's	POS	_	12	possessive	_
14	(	(	-LRB-	_	15	punct	_
15	GSK	gsk	NNP	p2=NN	10	dobj	_
16	)	)	-RRB-	_	15	punct	_
17	cancer	cancer	NN	_	19	hmod	_
18	-	-	HYPH	_	19	hyph	_
19	drug	drug	NN	_	20	nn	_
20	business	business	NN	_	10	dobj	10:A1=PPT
21	for	for	IN	_	10	prep	10:A3=VSP
22	up	up	IN	p2=RB	26	quantmod	_
23	to	to	TO	_	26	quantmod	_
24	US$	us$	$	p2=NNP	26	quantmod	_
25	16	0	CD	_	26	number	_
26	billion	#crd#	CD	_	21	pobj	_
27	,	,	,	_	7	punct	_
28	to	to	TO	_	29	aux	_
29	sell	sell	VB	pb=sell.01	7	infmod	_
30	most	most	JJS	_	29	dobj	29:A1=PPT
31	of	of	IN	_	30	prep	_
32	its	its	PRP$	_	34	poss	_
33	vaccines	vaccine	NNS	_	34	nn	_
34	business	business	NN	_	31	pobj	_
35	to	to	TO	p2=IN	36	aux	_
36	GSK	gsk	VB	p2=NNP|pb=gsk.01	29	advcl	_
37	for	for	IN	_	36	prep	36:A3
38	US$	us$	$	_	40	quantmod	_
39	7.1	0	CD	_	40	number	_
40	billion	#crd#	CD	_	37	pobj	_
41	,	,	,	_	7	punct	_
42	plus	plus	CC	_	7	cc	_
43	royalties	royalty	NNS	_	7	conj	_
44	,	,	,	_	3	punct	_
45	and	and	CC	_	3	cc	_
46	to	to	TO	_	47	aux	_
47	sell	sell	VB	pb=sell.01	3	advcl	_
48	its	its	PRP$	_	51	poss	_
49	animal	animal	NN	p2=JJ	51	nn	_
50	health	health	NN	_	51	nn	_
51	division	division	NN	_	47	dobj	47:A1=PPT
52	to	to	IN	_	47	prep	47:A2=GOL
53	Eli	eli	NNP	_	54	nn	_
54	Lilly	lilly	NNP	_	52	pobj	_
55	and	and	CC	_	54	cc	_
56	Co	co	NNP	_	54	conj	_
57	of	of	IN	_	54	prep	_
58	Indianapolis	indianapolis	NNP	_	57	pobj	_
59	for	for	IN	_	47	prep	47:A3=VSP
60	about	about	RB	p2=IN	63	advmod	_
61	US$	us$	$	_	63	quantmod	_
62	5.4	0	CD	_	63	number	_
63	billion	#crd#	CD	_	59	pobj	_
64	.	.	.	_	3	punct	_

1	Canada	canada	NNP	_	4	poss	_
2	's	's	POS	p2=VBZ	1	possessive	_
3	Valeant	valeant	NNP	_	4	nn	_
4	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	6	nsubj	6:A0
5	has	have	VBZ	_	6	aux	_
6	made	make	VBN	pb=make.LV	0	root	_
7	an	an	DT	_	9	det	_
8	unsolicited	unsolicited	JJ	_	9	amod	_
9	offer	offer	NN	_	6	dobj	6:AM-PRR
10	of	of	IN	_	9	prep	_
11	nearly	nearly	RB	_	14	advmod	_
12	US$	us$	$	_	14	quantmod	_
13	46	0	CD	_	14	number	_
14	billion	#crd#	CD	_	10	pobj	_
15	for	for	IN	_	9	prep	_
16	Botox	botox	NNP	p2=NN	17	nn	_
17	maker	maker	NN	_	18	nn	_
18	Allergan	allergan	NNP	_	15	pobj	22:A0
19	,	,	,	_	18	punct	_
20	which	which	WDT	_	22	nsubj	22:R-A0
21	has	have	VBZ	_	22	aux	_
22	turned	turn	VBN	pb=turn.05	18	rcmod	_
23	it	it	PRP	_	22	dobj	22:A1=PPT
24	down	down	RP	_	22	prt	22:C-V
25	,	,	,	_	18	punct	_
26	so	so	RB	_	27	advmod	_
27	far	far	RB	_	22	advmod	22:AM-TMP
28	.	.	.	_	6	punct	_

1	Pfizer	pfizer	NNP	p2=NN	4	poss	_
2	's	's	POS	_	1	possessive	_
3	latest	late	JJS	_	4	amod	_
4	offer	offer	NN	p2=VBP	5	nsubj	5:A1=PPT
5	increased	increase	VBD	pb=increase.01	0	root	_
6	from	from	IN	_	5	prep	5:A3=DIR
7	33	0	CD	_	8	num	_
8	percent	percent	NN	_	6	pobj	_
9	to	to	IN	_	6	prep	_
10	45	0	CD	_	11	num	_
11	percent	percent	NN	_	9	pobj	_
12	the	the	DT	_	13	det	_
13	ratio	ratio	NN	_	6	pobj	_
14	of	of	IN	_	13	prep	_
15	cash	cash	NN	_	14	pobj	_
16	AstraZeneca	astrazeneca	NNP	p2=NN	17	nn	_
17	shareholders	shareholder	NNS	_	19	nsubj	19:A0=PAG
18	would	would	MD	_	19	aux	19:AM-MOD
19	receive	receive	VB	pb=receive.01	13	rcmod	_
20	.	.	.	_	5	punct	_

1	The	the	DT	_	3	det	_
2	latest	late	JJS	_	3	amod	_
3	offer	offer	NN	_	6	nsubj	6:A0=PAG
4	would	would	MD	_	6	aux	6:AM-MOD
5	have	have	VB	_	6	aux	_
6	given	give	VBN	pb=give.01	0	root	_
7	them	them	PRP	_	6	iobj	6:A2=GOL
8	the	the	DT	_	9	det	_
9	equivalent	equivalent	NN	_	6	dobj	6:A1=PPT;17:A1=PPT
10	of	of	IN	_	9	prep	_
11	￡55	￡0	NN	p2=NNS	10	pobj	_
12	for	for	IN	_	9	prep	_
13	each	each	DT	_	15	det	_
14	AstraZeneca	astrazeneca	NNP	_	15	nn	_
15	share	share	NN	p2=VBP	12	pobj	_
16	,	,	,	_	9	punct	_
17	split	split	VBN	p2=VBD|pb=split.01	9	partmod	_
18	between	between	IN	_	17	prep	17:A2=PPT
19	1.747	0	CD	_	20	num	_
20	shares	share	NNS	_	18	pobj	_
21	of	of	IN	_	20	prep	_
22	the	the	DT	_	24	det	_
23	new	new	JJ	_	24	amod	_
24	company	company	NN	_	21	pobj	_
25	and	and	CC	_	24	cc	_
26	￡0.02476	￡0	NN	p2=CD	24	conj	_
27	in	in	IN	_	24	prep	_
28	cash	cash	NN	_	27	pobj	_
29	.	.	.	_	6	punct	_

1	It	it	PRP	_	2	nsubj	2:A0
2	said	say	VBD	pb=say.01	0	root	_
3	the	the	DT	_	4	det	_
4	offer	offer	NN	_	5	nsubj	5:A0
5	represented	represented	VBD	pb=represent.01	2	ccomp	2:A1=PPT
6	a	a	DT	_	9	det	_
7	45	0	CD	_	8	num	_
8	percent	percent	NN	_	9	nn	_
9	premium	premium	NN	p2=JJ	5	dobj	5:A1
10	to	to	IN	p2=TO	5	prep	5:A2
11	AstraZeneca	astrazeneca	NNP	_	14	poss	_
12	's	's	POS	_	11	possessive	_
13	share	share	NN	_	14	nn	_
14	price	price	NN	_	10	pobj	_
15	of	of	IN	_	14	prep	_
16	￡37.82	￡0	NN	p2=NNP	15	pobj	_
17	on	on	IN	_	5	prep	5:AM-TMP
18	April	april	NNP	_	17	pobj	_
19	17	0	CD	_	18	num	_
20	,	,	,	_	5	punct	_
21	before	before	IN	_	26	mark	_
22	rumors	rumor	NNS	_	26	nsubj	26:A1=PPT;27:A1=PPT
23	of	of	IN	_	22	prep	_
24	the	the	DT	_	25	det	_
25	deal	deal	NN	_	23	pobj	_
26	began	begin	VBD	pb=begin.01	5	advcl	5:AM-TMP
27	circulating	circulate	VBG	pb=circulate.01	26	xcomp	26:C-A1
28	.	.	.	_	2	punct	_

1	AstraZeneca	astrazeneca	NNP	_	4	nsubj	4:A0=PAG;9:A0=PAG
2	has	have	VBZ	_	4	aux	_
3	repeatedly	repeatedly	RB	_	4	advmod	4:AM-TMP
4	rejected	reject	VBN	pb=reject.01	0	root	_
5	Pfizer	pfizer	NNP	p2=NN	7	poss	_
6	's	's	POS	_	5	possessive	_
7	offers	offer	NNS	p2=NN	4	dobj	4:A1=PPT
8	,	,	,	_	4	punct	_
9	insisting	insist	VBG	pb=insist.01	4	advcl	4:AM-PRD
10	that	that	IN	_	13	complm	_
11	they	they	PRP	_	13	nsubj	13:A0=PAG
12	significantly	significantly	RB	_	13	advmod	13:AM-MNR
13	undervalue	undervalue	VBD	p2=VBP|pb=undervalue.01	9	ccomp	9:A1=PPT
14	the	the	DT	_	15	det	_
15	company	company	NN	_	13	dobj	13:A1=PPT
16	and	and	CC	_	15	cc	_
17	its	its	PRP$	_	18	poss	_
18	portfolio	portfolio	NN	_	15	conj	_
19	of	of	IN	_	15	prep	_
20	experimental	experimental	JJ	_	21	amod	_
21	drugs	drug	NNS	_	19	pobj	_
22	.	.	.	_	4	punct	_

1	The	the	DT	_	2	det	_
2	company	company	NN	_	9	nsubj	9:A0=PAG
3	and	and	CC	_	2	cc	_
4	British	british	JJ	_	6	amod	_
5	government	government	NN	_	6	nn	_
6	officials	official	NNS	_	2	conj	_
7	also	also	RB	_	9	advmod	9:AM-DIS
8	have	have	VBP	_	9	aux	_
9	raised	raise	VBN	pb=raise.01	0	root	_
10	concerns	concern	NNS	_	9	dobj	9:A1=PPT
11	about	about	IN	_	10	prep	_
12	the	the	DT	_	13	det	_
13	prospect	prospect	NN	_	11	pobj	_
14	of	of	IN	_	13	prep	_
15	job	job	NN	_	16	nn	_
16	cuts	cut	NNS	_	14	pobj	_
17	,	,	,	_	16	punct	_
18	facility	facility	NN	_	19	nn	_
19	closures	closure	NNS	_	16	conj	_
20	and	and	CC	_	19	cc	_
21	losing	lose	VBG	pb=lose.02	19	conj	_
22	some	some	DT	_	21	dobj	21:A1=PPT
23	of	of	IN	_	22	prep	_
24	the	the	DT	_	26	det	_
25	science	science	NN	_	26	nn	_
26	leadership	leadership	NN	_	23	pobj	_
27	in	in	IN	_	26	prep	_
28	the	the	DT	_	29	det	_
29	UK	uk	NNP	_	27	pobj	36:AM-LOC
30	,	,	,	_	29	punct	_
31	where	where	WRB	_	36	advmod	36:R-AM-LOC
32	London	london	NNP	_	34	hmod	_
33	-	-	HYPH	_	34	hyph	_
34	based	base	VBN	_	35	amod	_
35	AstraZeneca	astrazeneca	NNP	_	36	nsubj	36:A1=PPT
36	is	be	VBZ	pb=be.01	29	rcmod	_
37	the	the	DT	_	41	det	_
38	second	#ord#	RB	_	40	hmod	_
39	-	-	HYPH	_	40	hyph	_
40	biggest	big	JJS	p2=RBS	41	amod	_
41	drugmaker	drugmaker	NN	_	36	attr	36:A2=PRD
42	,	,	,	_	41	punct	_
43	behind	behind	IN	p2=RB	36	prep	_
44	GlaxoSmithKline	glaxosmithkline	NNP	_	43	pobj	_
45	.	.	.	_	9	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	nsubj	3:A0
2	has	have	VBZ	_	3	aux	_
3	made	make	VBN	pb=make.LV	0	root	_
4	assurances	assurance	NNS	_	3	dobj	3:AM-PRR
5	that	that	IN	p2=WDT	9	complm	_
6	such	such	JJ	_	7	amod	_
7	cuts	cut	NNS	_	9	nsubj	9:A1=PPT
8	would	would	MD	_	9	aux	9:AM-MOD
9	be	be	VB	pb=be.01	4	ccomp	_
10	limited	limited	JJ	p2=VBN	9	acomp	9:A2=PRD
11	.	.	.	_	3	punct	_

1	It	it	PRP	_	3	nsubj	3:A0=PAG;5:A0=PAG;16:A0
2	has	have	VBZ	_	3	aux	_
3	promised	promise	VBN	pb=promise.01	0	root	_
4	to	to	TO	_	5	aux	_
5	complete	complete	VB	p2=JJ|pb=complete.01	3	xcomp	3:A2=PPT
6	AstraZeneca	astrazeneca	NNP	_	11	poss	_
7	's	's	POS	_	6	possessive	_
8	research	research	NN	_	11	nn	_
9	and	and	CC	_	8	cc	_
10	development	development	NN	_	8	conj	_
11	hub	hub	NN	_	5	dobj	5:A1=PPT
12	in	in	IN	_	11	prep	_
13	Cambridge	cambridge	NNP	_	12	pobj	_
14	and	and	CC	_	5	cc	_
15	to	to	TO	_	16	aux	_
16	establish	establish	VB	pb=establish.01	5	conj	_
17	the	the	DT	_	19	det	_
18	new	new	JJ	_	19	amod	_
19	company	company	NN	_	22	poss	_
20	's	's	POS	_	19	possessive	_
21	tax	tax	NN	_	22	nn	_
22	residence	residence	NN	_	16	dobj	16:A1=PPT
23	,	,	,	_	16	punct	_
24	but	but	CC	_	16	cc	_
25	not	not	RB	_	26	neg	_
26	headquarters	headquarter	NNS	p2=NN	16	dobj	34:A0
27	,	,	,	_	26	punct	_
28	in	in	IN	_	26	prep	_
29	England	england	NNP	_	28	pobj	_
30	,	,	,	_	26	punct	_
31	which	which	WDT	_	34	nsubj	34:R-A0
32	would	would	MD	_	34	aux	34:AM-MOD
33	significantly	significantly	RB	_	34	advmod	34:A2=EXT
34	reduce	reduce	VB	pb=reduce.01	26	rcmod	_
35	its	its	PRP$	_	38	poss	_
36	future	future	JJ	p2=NN	38	amod	_
37	tax	tax	NN	_	38	nn	_
38	rate	rate	NN	_	34	dobj	34:A1=PPT
39	.	.	.	_	3	punct	_

